# Jennifer A. Wargo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jennifer-a-wargo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 89,241 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 127 |
| i10-index | 322 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5035427219 |
| ORCID iD | https://orcid.org/0000-0003-3438-7576 |
| Works | 1,509 |

## Researcher papers

Showing 12 of 13.

- [B cells and tertiary lymphoid structures promote immunotherapy response](https://scholariq.org/papers/b-cells-and-tertiary-lymphoid-structures-promote-immunotherapy-response/)
- [The human tumor microbiome is composed of tumor type–specific intracellular bacteria](https://scholariq.org/papers/the-human-tumor-microbiome-is-composed-of-tumor-type-specific-intracellular/)
- [Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma](https://scholariq.org/papers/defining-t-cell-states-associated-with-response-to-checkpoint-immunotherapy-in/)
- [Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine](https://scholariq.org/papers/potential-role-of-intratumor-bacteria-in-mediating-tumor-resistance-to-the/)
- [Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients](https://scholariq.org/papers/fecal-microbiota-transplant-promotes-response-in-immunotherapy-refractory/)
- [Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy](https://scholariq.org/papers/loss-of-pten-promotes-resistance-to-t-cell-mediated-immunotherapy/)
- [Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade](https://scholariq.org/papers/distinct-cellular-mechanisms-underlie-anti-ctla-4-and-anti-pd-1-checkpoint/)
- [EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib](https://scholariq.org/papers/egfr-mediated-reactivation-of-mapk-signaling-contributes-to-insensitivity-of-i/)
- [Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma](https://scholariq.org/papers/neoadjuvant-immune-checkpoint-blockade-in-high-risk-resectable-melanoma/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Targeting the gut and tumor microbiota in cancer](https://scholariq.org/papers/targeting-the-gut-and-tumor-microbiota-in-cancer/)
- [An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background](https://scholariq.org/papers/an-ultraviolet-radiation-independent-pathway-to-melanoma-carcinogenesis-in-the/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Gut microbiota and health](https://scholariq.org/topics/gut-microbiota-and-health/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.